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Abstract
The aim of the present study was to characterize the interactions of
antagonist G (H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2)-targeted
sterically stabilized liposomes with the human variant small cell
lung cancer (SCLC) H82 cell line and to evaluate the antiprolifera-
tive activity of encapsulated doxorubicin against this cell line.
Variant SCLC tumors are known to be more resistant to chemo-
therapy than classic SCLC tumors. The cellular association of
antagonist G-targeted (radiolabeled) liposomes was 20-30-fold
higher than that of non-targeted liposomes. Our data suggest that
a maximum of 12,000 antagonist G-targeted liposomes were inter-
nalized/cell during 1-h incubation at 37ºC. Confocal microscopy
experiments using pyranine-containing liposomes further confirmed
that receptor-mediated endocytosis occurred, specifically in the
case of targeted liposomes. In any of the previously mentioned
experiments, the binding and endocytosis of non-targeted lipo-
somes have revealed to be negligible. The improved cellular asso-
ciation of antagonist G-targeted liposomes, relative to non-tar-
geted liposomes, resulted in an enhanced nuclear delivery (evalu-
ated by fluorimetry) and cytotoxicity of encapsulated doxorubicin
for incubation periods as short as 2 h. For an incubation of 2 h, we
report IC50 values for targeted and non-targeted liposomes con-
taining doxorubicin of 5.7 ± 3.7 and higher than 200 µM doxorubi-
cin, respectively. Based on the present data, we may infer that
receptors for antagonist G were present in H82 tumor cells and
could mediate the internalization of antagonist G-targeted lipo-
somes and the intracellular delivery of their content. Antagonist G
covalently coupled to liposomal drugs may be promising for the
treatment of this aggressive and highly heterogeneous disease.
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Introduction
Small cell lung cancer (SCLC) is an ag-
gressive form of lung cancer that is highly
metastatic in humans (1). SCLC accounts
for 25% of all pulmonary cancers and, de-
spite an initial responsiveness to radiotherapy
and chemotherapy, the patient 5-year sur-
vival rate is only 5% (2). SCLC cell prolifera-
tion is driven by multiple autocrine and para-
crine growth loops, involving multiple mito-
genic neuropeptides, which play an impor-
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tant role in the aggressiveness of this disease
(3,4). Substances that interrupt the mitogen-
ic signals triggered by these neuropeptides
provide a new way of treating SCLC. The
hexapeptide, H-Arg-D-Trp-NmePhe-D-Trp-
Leu-Met-NH2, known as antagonist G, is one
such substance. It works by blocking the
action of multiple neuropeptides at the recep-
tor level (5,6) and has been shown to inhibit
the growth of SCLC cells both in vitro and in
vivo (4,6).
Entrapment of anticancer drugs in Stealth®
liposomes sterically stabilized with poly (eth-
ylene glycol) (Mr 2000) distearoylphosphati-
dylethanolamine conjugates, results in in-
creased tumor accumulation and improved
therapeutic efficacy. Coupling cancer cell-
specific ligands like monoclonal antibodies to
the surface of Stealth liposomal doxorubicin
(DXR) has proved to be an efficient means of
improving the cytotoxicity and therapeutic
efficacy of the encapsulated drug (7,8).
Small ligands like antagonist G may be more
advantageous than antibodies for targeting
purposes because they are chemically de-
fined and can be manufactured in large quan-
tities in pure form without biological con-
taminants. We have shown that the use of
antagonist G as a targeting ligand for Stealth
liposomes improved the intracellular delivery
and cytotoxicity of encapsulated DXR against
the classic SCLC H69 cell line compared to
non-targeted liposomes (9). This interaction
was shown to be peptide- and cell-specific
(9). However, SCLC is believed to undergo
a progression from a classical to a variant
form. This transformation is associated with
possible changes in surface proteins (recep-
tors), increased cell proliferation, amplifica-
tion of the c-myc proto-oncogene, and resis-
tance to chemotherapy (10,11). Patients pre-
senting variant SCLC are known to respond
less well to chemotherapy and have shorter
survival times (10).
The interaction between antagonist G and
variant SCLC cell lines has not been charac-
terized. Among the several variant SCLC cell
lines available, the H82 cell line is the one that
presents growing features (namely, growing
as floating cellular aggregates) that are iden-
tical to the ones presented by the classic
SCLC H69 cell line previously studied (9).
Therefore, here we studied the interaction of
antagonist G-targeted liposomes (SLG) with
the human variant SCLC H82 cell line and
evaluated the antiproliferative activity of en-
capsulated DXR.
Material and Methods
Material
Antagonist G (H-Arg-D-Trp-NmePhe-D-
Trp-Leu-Met-NH2) and substance P [1-9]
(H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-
NH2) were synthesized by the Alberta Pep-
tide Institute (Edmonton, AB, Canada). Fully
hydrogenated soy phosphatidylcholine
(HSPC), methoxy poly(ethylene glycol) (Mr
2000) distearoyl-phosphatidylethanolamine
(mPEG-DSPE) and N-(3'-(pyridyldithio)
propionoyl)amino-poly(ethylene glycol) (Mr
2000) distearoylphosphatidylethanolamine
(PDP-PEG-DSPE) were generous gifts of
Alza Corp. (Mountain View, CA, USA). All
other chemicals were of analytical grade
purity.
Cell line
The human variant SCLC cell line NCI-
H82 (ATCC HTB-175) was purchased from
the American Type Culture Collection and
cultured in RPMI 1640 supplemented with
10% (v/v) heat-inactivated fetal bovine se-
rum, 100 U/ml penicillin, 100 µg/ml strepto-
mycin (Gibco-BRL, Grand Island, NY, USA)
and maintained at 37ºC in a humidified incu-
bator containing 5% CO2.
Preparation of liposomes
Liposomes composed of HSPC:choles-
terol:mPEG-DSPE:PDP-PEG-DSPE at a
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2:1:0.08:0.02 molar ratio, were prepared by
lipid film hydration at 65ºC. For 8-hydroxy-
pyrene-1,3,6-trisulfonic acid, trisodium salt
(HPTS)-containing liposomes, the aqueous-
space label was added during the hydration
step (12). The resulting multivesicular prepa-
rations were then extruded at 65ºC sequen-
tially through 0.2 down to 0.08 µm polycar-
bonate membranes (Nucleopore, Pleasanton,
CA, USA) using a Lipex extruder (Lipex
Biomembranes, Vancouver, BC, Canada), to
provide vesicles averaging 100 nm in diam-
eter (13), as determined by dynamic light
scattering. Liposomes containing DXR
(Faulding Inc., Vaudreuil, PQ, Canada) were
prepared by the ammonium sulfate gradient
method (14). The loading efficiency of DXR
was greater than 95% and the liposomes
(with a mean diameter of 100 nm) routinely
contained approximately 200 µg DXR/µmol
phospholipid.
Antagonist G-targeted liposomes were
prepared by chemical coupling of the peptide
to the end of the PEG chain of PDP-PEG-
DSPE, according to a previously described
method (9). The amount of coupled peptide
was approximately 1 µg antagonist G/µmol
phospholipid. The same procedure was used
to couple a non-specific peptide, substance P
[1-9].
Phospholipid concentration was deter-
mined from either the specific activity counts
of the [1α,2α(n)-3H] cholesteryl hexadecyl
ether ([3H]-CHE) tracer or by the colorimet-
ric assay of Bartlett (15).
Association of liposomes with H82 cells
[3H]-CHE-liposomes were incubated with
1 x 106 cells/well on Falcon 48-well plates for
1 h at 37ºC, as described (7). In competition
experiments, the cells were incubated with
either free antagonist G (0-29 µg antagonist
G/well, for 30 min at 4º or 37ºC) or antago-
nist G-coupled non-radiolabeled liposomes
(0-0.6 µg antagonist G/well), or just lipo-
somes for 30 min at 37ºC before the addition
of [3H]-CHE-SLG (0.1 mM phospholipid/
well). After incubation, the cells were washed
three times with cold phosphate-buffered
saline (PBS), pH 7.4. The amount of lipo-
somes associated with cells was calculated
from the initial specific activity of [3H]-CHE-
liposomes by scintillation counting and is
reported as nmol phospholipid/106 cells.
In some experiments, cells were plated
onto 24-well plates at 2 x 106 cells/well.
HPTS-containing liposomes, with or with-
out coupled antagonist G, or coupled to
substance P [1-9], HPTS-SLP [1-9], were
added to each well (0.8 mM phospholipid/
well, a total volume of 0.4 ml) and maintained
at 37ºC in an atmosphere with 95% humidity
and 5% CO2 for 1 h. After washing three
times with PBS, the cells were visualized and
optically sectioned with an LSM-510 laser-
scanning confocal microscope (Carl Zeiss,
Jena, Germany) using an ultraviolet laser
with emission at 364 nm for scanning.
Doxorubicin uptake
The kinetics of DXR uptake was exam-
ined for the H82 cells as a function of time
both in whole cell extracts and in nuclei
isolated from 50 x 106 cells exposed to free
DXR or DXR-containing liposomes, with
(DXR-SLG) or without coupled antagonist
G (DXR-SL), or coupled with the non-
specific peptide substance P (DXR-SLP [1-
9]). The procedure for isolating nuclei and
determining their DXR content has been
previously described (9).
Cytotoxicity
In vitro cytotoxicity of free DXR and
various DXR-containing liposome formula-
tions was determined for H82 cells using the
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltet-
razolium bromide in vitro proliferation assay
(16). Briefly, H82 cells were seeded onto 96-
well plates at 3 x 104 cells/well and incubated
with different concentrations of free DXR,
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DXR-SL, DXR-SLG, free antagonist G,
empty SLG or free DXR mixed with empty
SLG (at 200 µg DXR/µmol phospholipid),
for 2, 24 or 48 h at 37ºC in an atmosphere
with 95% humidity and 5% CO2. At the end
of incubation the cells were gently washed
twice with PBS to remove the drug. The cells
were then maintained in fresh medium at
37ºC in an atmosphere of 95% humidity and
5% CO2 for up to 3 days from the beginning
of the study. Cell viability was then assessed
as described (17). Results are reported as
IC50 (µM DXR, unless otherwise stated),
determined from the dose-response curves.
Statistical analysis
The Student t-test was used to identify
statistically significant differences between
pairs of samples. Multiple comparisons of
IC50 (Table 1) were performed by analysis of
variance (ANOVA). The level of significance
was set at P < 0.05 for all analyses.
Results and Discussion
Small cell lung cancer proliferation is
driven by multiple autocrine and paracrine
growth loops involving, among others, sev-
eral neuropeptides including vasopressin,
bradykinin and gastrin-releasing peptide.
Binding of these neuropeptides to their re-
ceptors triggers a cascade of intracellular
signals (including an increase in intracellular
calcium) that culminates with DNA synthe-
sis and cell proliferation (4). SCLC is known
to undergo a transformation from a classical
form that responds to chemotherapy to a
variant form that grows rapidly, overex-
presses the proto-oncogene c-myc and is
refractory to treatment (10). The proto-
oncogene c-myc is thought to play an impor-
tant role in the regulation of cell division (18).
Chemotherapy itself can be one of the causes
for such differentiation (19). It has been
previously reported that classic SCLC cell
lines exhibit an increase of intracellular cal-
cium upon the binding of several autocrine
growth factors (namely, vasopressin) at the
receptor level, while most variant cell lines
(including the H82 cell line) show no increase
in intracellular free calcium (11,20). It was
hypothesized that one of the reasons for this
refractoriness could be the absence in variant
cells of receptors for many small mitogenic
neuropeptides (20). The presence or ab-
sence of these receptors could be critical for
the therapeutic success of target-based strat-
egies against SCLC.
In the present study we have shown that
the covalent attachment of antagonist G at
the end of PEG-grafted (Stealth) liposomes
gave results that were consistent with recep-
tor-mediated internalization of liposomes by
the human variant SCLC H82 cell line. This
resulted in improved intracellular delivery
and cytotoxic activity of encapsulated DXR
relative to non-targeted liposomes.
The differences in cellular association in
the experiments carried out at 4º and 37ºC
Table 1. Cytotoxicity of various doxorubicin formulations against H82 cells.
Incubation DXR-SL DXR-SLG DXR DXR + Empty SLG Free antagonist G
time (h) empty SLG (mM phospholipid) (µM antagonist G)
2 >200 5.7 ± 3.7 3.4 ± 1.2 2.2 ± 0.2 >1 148 ± 4.4
24 60.9 ± 22.9 5.5 ± 4.9 1.2 ± 0.2 1.1 ± 0.2 >1 57.8 ± 7.2
48 21.3 ± 7.7 6.4 ± 2.8 0.6 ± 0.5 0.8 ± 0.6 >1 39.3 ± 19.5
Data are reported as the mean ± SD of the IC50 values (µM DXR) for 3-7 independent experiments, unless
otherwise stated, and were extrapolated from the dose-response curves. DXR = doxorubicin; DXR-SL =
non-targeted liposomes containing doxorubicin; DXR-SLG = antagonist G-targeted liposomes containing
doxorubicin; SLG = antagonist G-targeted liposomes.
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with [3H]-CHE-SLG (Figure 1) suggests that
antagonist G-targeted liposomes were being
internalized by H82 cells. At 37ºC, where
both binding and internalization take place,
SLG associated with the cells approximately
20-30-fold more than SL, SLP [1-9] or SL in
the presence of free antagonist G. At 4ºC, a
2.2- to 2.7-fold decrease in the cellular asso-
ciation of SLG was observed, which is to be
expected if the component of cell-liposome
association due to liposome internalization by
the tumor cells was inhibited at this low
temperature. Based on the assumption that
there are 7.7 x 1012 liposomes/µmol phos-
pholipid (7), we estimate that, after a 1-h
incubation, within the phospholipid concen-
tration range tested, there were 3,600-12,000
SLG liposomes internalized/cell.
Images of optically sectioned cells ob-
tained by confocal microscopy showed that
after 1 h at 37ºC SLG liposomes containing
the fluorescent dye HPTS (HPTS-SLG) were
distributed both on the cell surface and intra-
cellularly (Figure 2A). Under the same con-
ditions, no staining was detectable when the
cells were treated with either HPTS-SL (Fig-
ure 2B) or HPTS-SLP [1-9] (Figure 2C).
Association of [3H]-CHE-SLG with H82
cells was competitively inhibited only when
cells were pre-incubated with non-radiola-
beled SLG (Figure 3B) at a concentration that
was 48-fold lower than the highest amount
of free antagonist G that showed no inhibi-
tion of binding either at 4º or at 37ºC (Figure
3A). This result is also consistent with the
explanation that the association of SLG with
H82 cells was taking place mainly through a
receptor-mediated process, possibly involv-
ing multivalent binding sites. The amount of
coupled antagonist G needed to reach 50% of
cell-liposome association inhibition was 0.03
µg (Figure 3B). In a control experiment,
liposomes pre-incubated with the tumor cells
did not interfere with the cell-liposome asso-
ciation of [3H]-CHE-SLG (data not shown).
The covalent linkage of antagonist G to the
PEG-grafted liposomes appears to have in-
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Figure 1. Association of [3H]-
CHE-labeled liposome formula-
tions with SCLC H82 cells. H82
cells (1 x 106 cells) were incu-
bated with different liposomal
formulations (0.1-0.8 mM phos-
pholipid (PL)/well) containing
SL (open circles) or SLP [1-9]
(inverted triangles) at 37ºC or
SLG at 4ºC (lozenges) or 37ºC
for 1 h (filled circles) or SL in the
presence of free antagonist G
at an antagonist G/phospholipid
molar ratio of 1:200 (open tri-
angles). Each point is the mean
± SD for 3-4 samples. SCLC = small cell lung cancer; SL = non-targeted liposomes; SLG
= antagonist G-targeted liposomes; SLP = substance P-coupled liposomes.
Figure 2. Association of HPTS-
containing liposomes with
SCLC H82 cells. H82 cells (2 x
106 cells) were incubated with
liposomes (0.8 mM phospho-
lipid/well) at 37ºC for 1 h. H82
cells were incubated with SLG
(A), SL (B) or SLP [1-9] (C).
After washing with cold PBS,
the cells were visualized with
an LSM-510 laser-scanning
confocal microscope. HPTS =
8-hydroxypyrene-1,3,6-trisul-
fonic acid, trisodium salt; SCLC
= small cell lung cancer; SLG =
antagonist G-targeted lipo-
somes; SL = non-targeted lipo-
somes; SLP = substance P-
coupled liposomes. Scale bar
for all panels = 10 µm.
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creased the avidity of the peptide for its
receptors due to the multivalent presentation
of the peptide, that is, the presence of
several attached-peptide molecules allows
one liposome to bind more than one receptor
at once. DeFrees et al. (21) have shown that
the use of sialyl Lewis glycolipid coupled to
liposomes was a stronger inhibitor of E-
selectin-dependent cell adhesion than free
glycolipid. Overall, these studies reinforce
Fluorescence Contrast
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the idea that liposomes might be a powerful
tool for the efficient presentation of ligands
to cell surface receptors that require multiva-
lent contact.
The increased levels of cell-liposome as-
sociation of SLG relative to SL or SLP [1-9]
resulted in a more efficient intracellular deliv-
ery of DXR when it was encapsulated in
antagonist G-targeted formulations, both to
the whole cells and to the nuclei (Figure
4A,B). When delivered by SLG, accumula-
tion of DXR, both into whole cells and nuclei,
was faster and higher (10- to 20-fold) than
when the drug was delivered either by SL or
SLP [1-9]. Interestingly, in whole cell ex-
tracts DXR from SLG accumulated more
rapidly and plateaued at 6 h compared to drug
accumulation in the nucleus, which pla-
teaued at around 12 h. This may be related to
either uptake of some free DXR released
from the liposomes prior to internalization or
to the release of the drug from endosomes
(22). The accumulation of free DXR both in
the whole cell extracts and in the nuclear
fractions, was more rapid and occurred to a
greater extent than that of the liposomal
samples. This does not necessarily lead to
improved tumor accumulation in vivo due to
the higher volume of distribution of free
DXR relative to that of liposomal DXR (23).
We then determined whether the im-
proved intracellular drug delivery by the
targeted formulation would translate into an
improved antiproliferative activity against the
H82 cell line (Table 1). Interestingly, after an
incubation of only 2 h, DXR-SLG was as
toxic as free DXR (P > 0.05) and approxi-
mately 35 times more toxic than DXR-SL (P
< 0.001). After 24- and 48-h incubations, the
differences in cytotoxicity between DXR-
SLG and free DXR were not significant (P >
0.05), and while the differences between
DXR-SLG and DXR-SL decreased, they
were still statistically significant (P < 0.001).
The absence of any differences between free
DXR and free DXR in the presence of empty
SLG at 200 µg DXR/µmol phospholipid (P >
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Figure 4. Kinetics of DXR or
DXR-containing liposome up-
take by SCLC H82 cells. Twenty
µM of free DXR (lozenges) or
DXR-containing liposomes
(DXR-SL, open circles; DXR-
SLG, filled circles, and DXR-SLP
[1-9], triangles), were incubated
with 50 x 106 H82 cells at 37ºC
for 24 h. DXR was measured in
whole cell extracts (A) or in iso-
lated nuclei (B). The back-
ground was subtracted from the
values at each time point. Each
point is the mean ± SD of 3
samples. DXR = doxorubicin;
SL = liposomes; SLG = antago-
nist G-targeted liposomes; SLP
= substance P-coupled lipo-
somes.
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Figure 3. Competitive inhibition
of the association of [3H]-CHE-
SLG with SCLC H82 cells. H82
cells (1 x 106 cells) were pre-
incubated for 30 min with: A, 0-
29 µg of free antagonist G, ei-
ther at 4ºC (lozenges) or 37ºC
(circles); B, 0-0.6 µg of antago-
nist G covalently linked to non-
radiolabeled SLG at 37ºC
(circles). Competitive inhibition
was determined by adding [3H]-
CHE-SLG (0.1 mM phospholipid
(PL)/well), either at 4º or 37ºC
and incubating for 1 h. Each
point is the mean ± SD for 3
samples. [3H]-CHE-SLG = [1α,
2α(n)-3H] cholesteryl hexadecyl
ether-antagonist G-targeted li-
posomes; SCLC = small cell
lung cancer; SLG = antagonist
G-targeted liposomes.
Antagonist G-coupled liposomes (µg)
1191
Braz J Med Biol Res 37(8) 2004
Antagonist G-mediated targeting of liposomes
0.05), independent of incubation time, sug-
gested that there was no contribution of
antagonist G to the observed cytotoxicities.
The IC50 values for empty SLG and free
antagonist G were much higher than the
concentrations of phospholipid and antago-
nist G at the IC50 for DXR-SLG at all incu-
bation times, confirming that the cytotoxic
activity of this sample was exclusively due to
the more efficient delivery of the encapsu-
lated drug by SLG.
The cytotoxicity results demonstrate that
binding and internalization of DXR-SLG con-
tribute to an increased level of cytotoxicity
against the H82 cell line compared to DXR-
SL. The results for DXR uptake into whole
cells plateaued before that in isolated nuclei,
suggesting that the release of DXR from the
endosomes may be delayed. How this delay
in DXR release from endosomes, which will
affect the rate at which the drug reaches
intracellular sites of action, impinges on the
overall cytotoxicity of targeted formulations
remains to be assessed. In spite of a possible
delay in the release of DXR from the endo-
somes, however, we observed that the tar-
geted formulations had a cytotoxicity that
was similar to that of the free drug in vitro.
Overall, based on the data presented here,
it may be inferred that receptors for antago-
nist G in H82 cells were present and func-
tionally active, and were not turned off by the
differentiation process that took place. These
results, along with the high affinity of an-
tagonist G for the vasopressin receptor (6),
which is expressed on the surface of variant
SCLC cells (11,24), suggest that this could
be the main receptor involved in the internal-
ization of SLG. Moreover, the small differ-
ences between the amounts of coupled an-
tagonist G necessary to inhibit 50% of cellu-
lar association of SLG, both in the H82
variant and the classical H69 SCLC cell lines
(9), suggested a similar density of receptors
for antagonist G between these two subtypes
of SCLC cells. This was confirmed by the
similar cellular association patterns of either
fluorescent radiolabeled liposomes or DXR-
containing liposomes (9).
The similar cytotoxic activity of DXR-
SLG against the H82 variant and the H69
SCLC cell lines (9), where c-myc proto-
oncogene is either not detectable or present
at only trace levels (18), suggests that the
delivery of liposomal DXR through receptor-
mediated endocytosis could be an efficient
way to overcome the problems of c-myc
overexpression by variant cells. Moreover,
the long circulation half-lives of SLG (9), a
crucial feature for in vivo applications, give
antagonist G-targeted liposomes containing
DXR, or antisense oligonucleotides against
c-myc, potential for the treatment of variant
small cell lung cancer.
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